Monitor for the definitive proxy statement/prospectus and the closing of the underlying business combination. The effectiveness removes a regulatory hurdle, but the deal terms and shareholder vote remain key catalysts.
HOWL drugs
HOWL drug pipeline →- ● neridronate 6/10 Phase 3
- ▼ WTX-124 3/10 unknown — not confirmed this session (SecBot's FDA/ClinicalTrials.gov ingestion holds no WTX-124 records; external web s
- ● WTX-330 2/10 Unknown/unverified — no Phase 2/3 industry-sponsored records for WTX-330 exist in SecBot's ingested ClinicalTrials.gov d
- All HOWL drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 13 $0.9803entry
- T+1 · 18h ago +1.07%α +2.98% · $0.9908
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Werewolf Therapeutics' S-4 registration statement (File No. 333-299079) became effective on November 12, 2026, under the 1933 Act. This effectiveness allows the company to proceed with the business combination or exchange offer contemplated by the S-4, likely involving the issuance of securities in connection with a merger or acquisition.
Key Facts
- Effectiveness date: November 12, 2026
- Registration statement type: S-4 (business combination or exchange offer)
- SEC File Number: 333-299079
- Company: Werewolf Therapeutics, Inc. (Ticker: HOWL)
Financial Impact
No financial terms disclosed in the effectiveness notice. The S-4 registration statement likely involves the issuance of shares or other securities in a merger or acquisition, but no dollar amounts or share counts are provided.
Risk Factors
- No financial details (deal value, dilution, exchange ratio) are available from this filing
- The S-4 may involve a reverse merger or acquisition with uncertain terms
- Shareholder approval and other closing conditions remain outstanding
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-003522 |
| Document: 9999999995-26-003522-index.html | 9999999995-26-003522 |
| Document: 9999999995-26-003522.txt | 9999999995-26-003522 |
Track record
31 reports on HOWL
12 of 16 bullish or bearish reports moved the stock their way by T+5. Best: +51.32% at T+60 after the Apr 27, 2026 report. 13 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $0.9500 Now $0.9910 +4.32% settles Nov 23
- Nov 13, 20264d ago EFFECT Neutral 4/10 Viewing Entry $0.9803 Now $0.9910 +1.09% settles Nov 20
- Nov 10, 20266d ago S-4/A Neutral 5/10 Entry $0.9889 Now $0.9910 +0.21% settles Nov 18
- Nov 9, 20267d ago 425 Neutral 5/10 Entry $0.9700 Now $0.9910 +2.16% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $1.01 to $0.9908 Now $0.9910 −1.88% ▼ −1.90% −0.21% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $1.01 to $0.9908 Now $0.9910 −1.88% ▼ −1.90% −0.21% vs SPY
- Oct 26, 202621d ago S-4/A Bearish 5/10 Entry $1.04 to $1.07 Now $0.9910 +4.71% ▼ −2.88% −4.87% vs SPY
- Sep 22, 20267w ago S-4 Bearish 7/10 Entry $0.9894 to $0.9223 Now $0.9910 −0.16% ▲ +6.78% +6.11% vs SPY
- Sep 21, 20268w ago SC 13G Neutral 3/10 Entry $0.9800 to $0.9300 Now $0.9910 +1.12% ▼ −5.10% −4.08% vs SPY
- Aug 21, 202612w ago 425 Bullish 7/10 Entry $0.8740 to $0.9433 Now $0.9910 +13.39% ▲ +7.93% +7.46% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers